Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
about
Follicular lymphoma: 2012 update on diagnosis and managementAlkylating agents for Waldenstrom's macroglobulinaemiaChronic lymphocytic leukemia: a clinical review including Korean cohortsFollicular lymphoma: 2011 update on diagnosis and managementDiagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesReview of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patientsUpdate on therapeutic options in Waldenström macroglobulinemiaRituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysisFludarabine in Waldenstrom's macroglobulinemia.A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapFCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.Waldenstrom macroglobulinemiaWaldenstrom macroglobulinemia: prognosis and management.Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma.Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphomaWaldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosisFludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy.Profiling CD antigens on leukaemias with an antibody microarray.A review of pharmacologic options for previously untreated chronic lymphocytic leukemia.The future of CD20 monoclonal antibody therapy in B-cell malignancies.Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.Waldenström macroglobulinemia: from biology to treatment.Current and future therapeutic approach for Waldenström's macroglobulinemia.How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
P2860
Q22252956-DCB64B17-B2B6-49D6-8E5A-D482524893D1Q24241090-45501C7F-5063-4CD7-B4BC-E5B27B9E0358Q26752467-9C8A2A0A-5407-4590-A45F-DA6734B8A444Q26851450-0267A81F-55C4-4E3C-9767-4D1734240F11Q28290236-6CB538F0-8EE8-4E61-A527-092C68BC044DQ28291793-07A60E17-2630-4056-A662-3B505F6B352EQ28304195-01B76AEB-1C5B-4D3F-89F6-82339E55F643Q33375915-7EE518ED-A7A2-4937-8D7E-F3364735F1B8Q33391919-430FC166-2380-41A1-AA4E-3AD78FA7D1A7Q33395066-53F70898-BEEF-460F-8833-E72608AC70DAQ33400780-F79D4B33-A072-4E36-8942-A7F88A3B6209Q33408517-CC867655-D767-4CD5-84B0-5386D9854DB2Q33421444-5AE89879-A95F-46DA-9B54-6E7D00F59254Q33438490-0951FD14-A721-462B-BB91-879E5AA22ADCQ33942272-B21B7E04-72C0-4EDB-AA09-F9040BB86A01Q34099792-2EA9BCC9-AFFF-445F-AE9E-EDA8D826FCCCQ34351916-67A7E9DB-6AF7-4629-AD37-DD7299D8526FQ34433926-915F0B34-7A75-4507-9646-AED25D7C084FQ34585773-E6103FAE-1484-42C6-A1D6-086C54A575A7Q35097328-8E1B2492-57E3-4178-9B64-BCF32DF781EDQ35244911-DAD7C47B-DB21-48F5-8391-182CB00125CDQ35430828-9ACBC3E7-2827-4DD9-888E-8591603466DAQ35524728-DB208C74-D466-4C3D-9258-2340E9FB7BC1Q35571040-32CA1305-AC8A-46A3-A6E9-9108F17F0525Q35786490-84310A47-EBF3-4574-AE4B-94ACA9D6D836Q35806665-E90F8E84-6FEE-4324-8DC9-DF961ADA68C1Q37231130-26ABD5BD-6F78-4650-9349-FAC54E8F69EFQ37418300-1864570B-531C-4FFD-BE22-BF556BAB3A4BQ37677899-4CB1F88E-0B97-4063-A341-C1D895C7AD11Q37724396-667ABCA5-D5A9-4646-9F80-4EB62F454C9DQ38042439-C1892628-DB51-44D9-9D55-18F62F1798DAQ38106512-4580A936-B386-4B32-86C6-ABC3F03DD332Q38176969-F5E5012F-2A6A-4624-91AE-A158F75A02BCQ38206820-B56CC0A9-4C76-4D9D-933D-7A420843E6D2Q38248474-D5BE3868-1BAD-47F4-B470-DB0E321F066EQ38594531-E88BB38D-56E9-4E00-99E8-881E95DB9F81Q39044362-8BC6B598-F6DD-4691-A064-E8C7D576B13EQ39639283-B94F542A-5A41-4B97-9F38-408D594C5140Q40773209-627EB068-7BEE-4177-9809-1C11B06558CBQ42852282-A8007BB2-F7C6-4DF6-92E4-F1223F8500BF
P2860
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Fludarabine, cyclophosphamide, ...... indolent non-Hodgkin lymphoma.
@en
type
label
Fludarabine, cyclophosphamide, ...... indolent non-Hodgkin lymphoma.
@en
prefLabel
Fludarabine, cyclophosphamide, ...... indolent non-Hodgkin lymphoma.
@en
P2093
P2860
P356
P1433
P1476
Fludarabine, cyclophosphamide, ...... indolent non-Hodgkin lymphoma
@en
P2093
David Westerman
Dennis Carney
E Henry Januszewicz
H Miles Prince
John F Seymour
Katherine I Lin
P2860
P304
P356
10.1002/CNCR.21882
P407
P577
2006-06-01T00:00:00Z